Zobrazeno 1 - 10
of 359
pro vyhledávání: ''
Autor:
Daniel Moj, Nicola Ammer, Babette Aicher, Jan-Georg Wojtyniak, Thorsten Lehr, Michael Teifel, Herbert Sindermann, Hannah Britz, Nina Hanke
Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors. The aim of this study was to establish a physi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c5e9a18956370d7aca5ee1061fd910
Autor:
Caroline Flora Samer, Camille Lenoir, Amine Niederer, Jules Alexandre Desmeules, Victoria Rollason, Youssef Daali
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 1, Pp 30-43 (2022)
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 1, Pp 30-43 (2022)
Xenobiotics can interact with cytochromes P450 (CYPs), resulting in drug–drug interactions, but CYPs can also contribute to drug–disease interactions, especially in the case of inflammation, which downregulates CYP activities through pretranscrip
Publikováno v:
Clinical Pharmacology in Drug Development
GLPG1205 is a novel agent being investigated for the treatment of idiopathic pulmonary fibrosis. GLPG1205 may be concomitantly administered with pirfenidone in future clinical development; therefore, the potential for GLPG1205 to interact with enzyme
Publikováno v:
Clinical Pharmacology & Therapeutics. 109:1618-1630
Clinical assessment of drug-drug interactions (DDIs) in children is not a common practice in drug development. Therefore, physiologically-based pharmacokinetic (PBPK) modeling can be beneficial for informing drug labeling. Using ivabradine and its me
Autor:
Brian F. Kiesel, Sarah Taylor, Jan H. Beumer, Jianxia Guo, Nupur Chaphekar, Edward Chu, Anand Joshi, Charles A. Kunos, Reyna Jones, Raman Venkataramanan
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: To investigate the metabolic pathways of triapine in primary cultures of human hepatocytes and human hepatic subcellular fractions; to investigate interactions of triapine with tenofovir and emtricitabine; and to evaluate triapine as a perpe
Autor:
Sauzanne Khalilieh, Tamara D. Cabalu, Yuhsin Kuo, Sasha McClain, Larissa Wenning, Ilias Triantafyllou, Yang Liu, Daniel P. Dreyer, Rosa I. Sanchez, S. Aubrey Stoch, Marian Iwamoto, Ka Lai Yee, Kerry L. Fillgrove
Publikováno v:
The Journal of Clinical Pharmacology. 61:394-405
Doravirine, a novel nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus 1 (HIV-1), is predominantly cleared by cytochrome P450 (CYP) 3A4 and metabolized to an oxidative metabolite (M9). Coadministration wit
Publikováno v:
The Journal of Clinical Pharmacology. 60:1314-1323
The effects of itraconazole on the pharmacokinetics of rovatirelin were investigated in an open-label, single-sequence drug-drug interaction study in 16 healthy subjects. Subjects were administered a single oral dose of rovatirelin (1.6 mg) on day 1
Publikováno v:
European Journal of Clinical Pharmacology
Purpose Peficitinib is an oral pan-Janus kinase inhibitor for the treatment of rheumatoid arthritis. Co-administration of peficitinib with metformin, a type 2 diabetes therapy, can occur in clinical practice. Hepatic and renal uptake of metformin is
Autor:
Felix Stader, Thierry Buclin, Monia Guidi, Susana Alves Saldanha, Matthias Cavassini, Laurent A. Decosterd, Catia Marzolini, Perrine Courlet, Marcel Stoeckle, Chantal Csajka
Publikováno v:
Clinical Pharmacokinetics
Clinical pharmacokinetics, vol. 59, no. 8, pp. 1037-1048
Clinical pharmacokinetics, vol. 59, no. 8, pp. 1037-1048
Background People living with HIV (PLWH) are aging and experience age-related physiological changes and comorbidities. Atorvastatin is a widely prescribed lipid-lowering agent metabolized by cytochrome P450 (CYP) 3A4, whose hepatocyte uptake is facil
Autor:
Awodayo O. Adepiti, Ayorinde Adehin, Oluseye O. Bolaji, Babatunde Ayodeji Adeagbo, Anthony A. Elujoba
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 45:81-88
MAMA decoction (MD) is an antimalarial product prepared from the leaves of Mangifera indica L. (Anacardiaceae), Alstonia boonei De Wild (Apocynaceae), Morinda lucida Benth (Rubiaceae) and Azadirachta indica A. Juss (Meliaceae). A previous report show